Mental Health Outcomes No Better for Teens Undergoing RYGB
WEDNESDAY, Jan. 22, 2020 -- Mental health outcomes do not appear to improve for obese adolescents undergoing Roux-en-Y gastric bypass, according to a study published online Jan. 21 in The Lancet Child & Adolescent Health.
Kajsa Järvholm, Ph.D., from Skåne University Hospital in Malmö, Sweden, and colleagues recruited adolescents aged 13 to 18 years with a body mass index of 40 kg/m² or higher or 35 kg/m² or higher in addition to obesity-related comorbidity who had failed comprehensive conservative treatment. Mental health outcomes were compared over five years of follow up for 81 adolescents who underwent Roux-en-Y gastric bypass surgery and 80 controls who received conventional treatment.
The researchers observed no difference between the groups in the proportion of participants prescribed psychiatric drugs in the years before study inclusion or after the intervention. Before baseline, no difference was noted between the groups in treatment for mental and behavioral disorders. In the five years after obesity treatment, adolescents in the surgical group had more specialized psychiatric treatment than those in the control group. Few patients discontinued psychiatric treatment after surgery. In the surgical group, self-esteem was improved after five years versus baseline, but no improvement was seen in overall mood. Relative to baseline, binge eating was improved at five years.
"We suggest that long-term mental health support should be required in programs providing adolescent metabolic and bariatric surgery," the authors write.
Several authors disclosed financial ties to the pharmaceutical and nutrition industries.
© 2020 HealthDay. All rights reserved.
Posted: January 2020
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.